July 28, 2017 (Shareholders Foundation) - An investigation on behalf of investors of United Therapeutics Corporation (NASDAQ:UTHR) shares over potential securities laws violations by United Therapeutics and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of United Therapeutics Corporation (NASDAQ:UTHR) concerning whether a series of statements by United Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

United Therapeutics Corporation reported that its annual Total Revenue increased from over $1.46 billion in 2015 to over $1.59 billion in 2016 and that its Net Income grew from $651.64 million in 2015 to $713.70 million in 2016.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) grew to as high as $168.16 per share in February 2017.

On July 27, 2017, United Therapeutics Corporation disclosed that it has set aside $210 million in connection to a possible settlement with the U.S. Department of Justice (DOJ) whether the companys contributions to patient-assistance charity groups violate federal laws against kickbacks and false claims. The DOJ previously subpoenaed United Therapeutics Corporation for information about its contributions to non-profit organizations that provide financial assistance to patients with out-of-pocket drug costs. United Therapeutics Corporation stated that it expects any settlement would also include a corporate integrity agreement, and the company may incur significant future costs to comply with that agreement.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) declined to as low as $123.05 per share on July 27, 2017.